CVS Health Corp (CVS-N)
289 watching
NYSE:CVS
93.77
0.58
(0.62%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Jul 7, 2022, 2:53 pm
0
TOP PICK
Stockchase Research Editor: Michael O'Reilly We again reiterate CVS, a top retail pharmacy and health care insurance company, as a TOP PICK. It trades at 1.6x book value and forward earnings for next year project a PE of 10x earnings compared to peers at 14x. It pays a good dividend backed by a payout ratio under 40% of cash flow. We like that it has continued to build cash reserves, while aggressively retiring debt and buying back shares. We continue to recommend the trailing stop at $85, looking to achieve $117 -- upside potential of 25%. Yield 2.36% (Analysts’ price target is $117.22)
specialty stores
$92.660
Unknown
BUY
Inexpensive and pays a good dividend as the economy stalls in purgatory.
specialty stores
BUY
Real estate component, acquisitions? Not a real estate play. Unique business model with retail pharmacy and PBM and health insurer all in one company. Balance sheet is in great shape. Gobs of free cashflow, low PE of less than 9. Can't speak to future acquisitions.
specialty stores
BUY
Are well-positioned to a shift to value-based care, which is an important healthcare trend.
specialty stores
TOP PICK
Stockchase Research Editor: Michael O'Reilly We again reitereate this top retail pharmacy and health care insurance company as a TOP PICK. Sales are up over 8% over the year with net income of $8 billion. It pays a good dividend backed by a payout ratio under 40% of cash flow. We like that it has continued to build cash reserves, while aggressively retiring debt and buying back shares. We recommend moving the stop loss (from $90) down to $85, looking to achieve $117 -- upside potential of 24%. Yield 2.29% (Analysts’ price target is $117.39)
specialty stores
WEAK BUY
Model price of $100, only 3% upside. A consumer discretionary, not a staple. Not hit as much as others. Safe, but he wouldn't be aggressive with these names in a bear market. He favours WBA. Yield is 2.2%.
specialty stores
TOP PICK
Defensive value name. Expectations that EPS growth will grow by high single digits or low doubles. Largest drugstore chain, leading pharmacy benefits manager. Aetna purchase added to revenue growth. Shareholder friendly. Beat earnings and raised guidance this week. Beat analysts expectations for 25 consecutive quarters. 12x forward earnings. Trading at discount to historical median. Yield is 2.21%. (Analysts’ price target is $117.86)
specialty stores
TOP PICK
More than just America's leading pharmacy. Vertically integrated colossus. #4 in the Fortune 500, and they got there through acquisitions. Earnings beat today, earnings grew YOY by 9%. Tweaked up guidance. Pivoting away from slower-growing retailer and toward faster-growing, upstream managed care and insurance. Showing financial strength with share buybacks. Trades at 12x earnings, still in middle innings. Lots of visibility in a murky economic environment. Yield is 2.29%. (Analysts’ price target is $117.53)
specialty stores
TOP PICK
This drugstore chain is vertically integrated by owning health insurer Aetna, and many of their stores include health hubs where medical personnel including nurses to address people's chronic health issues at a low cost. Their 2021 was solid, driven by vaccinations, but 2022 will be flat. He projects 6-7% annual growth, trades at 12x earnings. Well managed. They fill over 1 billion prescriptions a year. (Analysts’ price target is $117.53)
specialty stores
BUY
They report Wednesday. They capitalized on vaccinations and people have rediscovered the chain and like it.
specialty stores
HOLD
Safety trade. Healthcare solutions. Very good future. Over $8 EPS for 2022. New CEO is doing a good job.
specialty stores
PAST TOP PICK
(A Top Pick Jan 22/21, Up 38.85%) Pretty low multiple. In debt reduction mode. In future, great free cashflow, share buybacks, more acquisitions, pay down debt. Likes this better than peers as it's more than just a pharmacy; it's an integrated provider.
specialty stores
TOP PICK
Stockchase Research Editor: Michael O'Reilly This owner of 10,000 pharmacies across the US, who fills more than 20% of all prescriptions in the country, is reiterated again as a TOP PICK. The company announced a partnership with MSFT to bring more cloud based services to its customers, which should reduce costs and help retain customers. Forward earnings project the stock at 11x earnings, compared to peers at 15x and it trades under 2x book. It has been increasing cash reserves, while aggressively retiring debt. It pays a good dividend, backed by a payout ratio under 40% of cash flow. We would recommend adjusting the stop to $90.00, looking to achieve $117.50 - upside potential over 16%. Yield 2.18% (Analysts’ price target is $117.52)
specialty stores
DON'T BUY
Great job operationally. Earnings have grown nicely. 2022 will be relatively flat, depending on how well they can push through prices. 10-13x earnings, not expensive. Yield is 2%, not growing quickly. Probably better places to be such as COST or DOL, which he owns. More defensive than he'd want right now.
specialty stores
BUY
Healthcare stock outlook Healthcare stocks haven't done that well, so certain sectors hold potential. Careful with biotechs which have been hit hard by this correction, down over 50% from their peaks. CVS he likes--it owns Aetna, a health insurer, and are transforming their storefronts into mini-health hubs. All good. Also, he likes their pharma business. A well-rounded company.
specialty stores
CVS Health Corp(CVS-N) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 19
Neutral - Hold Signals / Votes : 3
Bearish - Sell Signals / Votes : 1
Total Signals / Votes : 23
CVS Health Corp(CVS-N) Frequently Asked Questions
What is CVS Health Corp stock symbol?
CVS Health Corp is a American stock, trading under the symbol CVS-N on the New York Stock Exchange (CVS). It is usually referred to as NYSE:CVS or CVS-N
Is CVS Health Corp a buy or a sell?
In the last year, 23 stock analysts published opinions about CVS-N. 19 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for CVS Health Corp.
Is CVS Health Corp a good investment or a top pick?
CVS Health Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for CVS Health Corp.
Why is CVS Health Corp stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is CVS Health Corp worth watching?
23 stock analysts on Stockchase covered CVS Health Corp In the last year. It is a trending stock that is worth watching.
What is CVS Health Corp stock price?
On 2022-07-07, CVS Health Corp (CVS-N) stock closed at a price of $93.77.
